Synergy Pharmaceuticals, based in New York City, is a biopharmaceutical company focused on gastrointestinal therapies.
Here are five things to know.
1. Synergy's proprietary GI platform is based on uroguanylin, a naturally occurring human GI peptide that supports normal bowel function.
2. The company's proprietary platform includes Trulance, a once-daily tablet approved for adults with chronic idiopathic constipation and IBS with constipation.
3. Trulance (plecanatide) is structurally identical to uroguanylin with the exception of one amino acid. Trulance is contraindicated in patients less than six years old.
4. Synergy is currently developing dolcanatide for ulcerative colitis.
5. Synergy became a public company in July 2008 and is currently listed on NASDAQ.
More articles on gastroenterology:
GI leader to know: Dr. Walter Hassig of Digestive Health Specialists
Olympus implementing InterSystems HealthShare to facilitate image sharing — 3 insights